We advised Oruka on the offering

Davis Polk advised Oruka Therapeutics, Inc. as issuer in connection with its SEC-registered at-the-market offering program. Pursuant to the terms of the program, Oruka may issue and sell shares of its common stock, par value $0.001 per share, with an aggregate value of up to $200 million. The common stock is listed on the Nasdaq Global Market under the symbol “ORKA.”

Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel biologics designed to set a new standard for the treatment of chronic skin diseases.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Paula Gergen and Erica F. Buonanno. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post